Literature DB >> 22117092

Choice of long-acting insulin therapy for type 2 diabetes: how can treatment for older people be optimized?

Andrew J Krentz, Alan J Sinclair.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22117092     DOI： 10.2165/11597820-000000000-00000

Source DB:  PubMed          Journal:  Drugs Aging        ISSN： 1170-229X            Impact factor:   3.923


× No keyword cloud information.
  29 in total

1.  How small changes led to big profits for insulin manufacturers.

Authors:  Deborah Cohen; Philip Carter
Journal:  BMJ       Date:  2010-12-15

Review 2.  Insulin analogues.

Authors:  Irl B Hirsch
Journal:  N Engl J Med       Date:  2005-01-13       Impact factor: 91.245

Review 3.  Hypoglycaemia in Type 2 diabetes.

Authors:  Simon R Heller
Journal:  Diabetes Res Clin Pract       Date:  2008-12-15       Impact factor: 5.602

Review 4.  Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis.

Authors:  E Mannucci; M Monami; N Marchionni
Journal:  Diabetes Obes Metab       Date:  2008-07-29       Impact factor: 6.577

Review 5.  Glucose control in the older patient: from intensive, to effective and safe.

Authors:  Ligia J Dominguez; Giuseppe Paolisso; Mario Barbagallo
Journal:  Aging Clin Exp Res       Date:  2009-11-17       Impact factor: 3.636

6.  The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.

Authors:  Matthew C Riddle; Julio Rosenstock; John Gerich
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

7.  Three-year efficacy of complex insulin regimens in type 2 diabetes.

Authors:  Rury R Holman; Andrew J Farmer; Melanie J Davies; Jonathan C Levy; Julie L Darbyshire; Joanne F Keenan; Sanjoy K Paul
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 8.  Use of short-acting insulin aspart in managing older people with diabetes.

Authors:  Eltayeb Marouf; Alan J Sinclair
Journal:  Clin Interv Aging       Date:  2009-05-14       Impact factor: 4.458

9.  Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-07-16       Impact factor: 10.122

10.  Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study.

Authors:  J Rosenstock; V Fonseca; J B McGill; M Riddle; J-P Hallé; I Hramiak; P Johnston; M Davis
Journal:  Diabetologia       Date:  2009-06-13       Impact factor: 10.122
View more
  1 in total

Review 1.  Optimal glycaemic control in elderly people with type 2 diabetes: what does the evidence say?

Authors:  Supriya Mathur; Nicola N Zammitt; Brian M Frier
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.